R&D Projects


Platform for rapid detection of treatable molecular alterations by liquid and solid biopsies.

Cancer is one of the leading causes of death worldwide. It is estimated that 22 million people will be diagnosed with a neoplastic process in 2030. One of the main causes of this disease is the appearance of somatic mutations, especially “point mutations”, which appear 95% of the time in solid tumours.

The most widely used technologies for the search for biomarkers, both in tumour tissue and in liquid biopsy samples, include next generation PCR (qRealTime and RealTime PCR), Next Generation Sequencing (NGS) platforms, and digital PCR (dPCR). Although all these platforms promise a sensitivity of over 98% and a specificity (PPV) of over 99%, according to our experience, together with that of other authors, this is far from realistic, and most of the predefined gene panels are redundant and uninformative, with low levels of scientific evidence, and with them being of little value in clinical use.

22 mill.

of people will be diagnosed with cancer in 2030 due to an abnormal cell growth


The technologies most commonly used in the search for biomarkers have little value in clinical use.

Based on these limitations, the aim of the project is to develop a platform for the identification of actionable genetic alterations, genetic alterations for which there is a drug, based on dPCR technology, from solid tissue samples and liquid biopsies from cancer patients. This type of platform is cost-effective, offers enormous flexibility to analyse only mutations with clinical value, with high levels of scientific evidence, and with response times of hours, thereby transforming the analysis of liquid biopsies from cancer patients into a useful tool that helps the doctor in making decisions.

To achieve the objectives

Expediente: RTC2019-006918-1 2020-2023

To ensure the success of the project, Atrys Health S.A. collaborates closely with the HM Hospitales group. This project has been funded by the Ministry of Science, Innovation, and Universities within the CHALLENGES-COLLABORATION Sub-programme, 2019 Call. The project is co-funded by the European Union with the aim of promoting technological development, innovation, and quality research.

Financial backers

Related projects



Sistema experto para diagnóstico y tratamiento personalizado en pacientes con cáncer

Read more


Plataforma para la toma de decisiones en el diagnóstico y el tratamiento oncológico

Read more